Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides

Journal of General Virology

Volumn 85, Issue 10, 2004, Pages 2893-2901

  Moreau, E ^a   Belliard, G ^b   Partidos, C D ^b   Pradezinsky, F ^a   Le Buanec, H ^c   Muller, S ^b   Desgranges, Claude ^a,d  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPITOPE; NEUTRALIZING ANTIBODY; REGULATOR PROTEIN; SYNTHETIC PEPTIDE; TRANSACTIVATOR PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 TAT VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; AUTOCRINE EFFECT; B LYMPHOCYTE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE COURSE; DRUG DESIGN; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MACACA; MOUSE; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RABBIT; SPECIES DIFFERENCE; T LYMPHOCYTE; TRANSACTIVATION; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS REACTIVATION; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; IMMUNIZATION; IMMUNOLOGY; LONG TERMINAL REPEAT; PHYSIOLOGY;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; ORYCTOLAGUS CUNICULUS;

AIDS VACCINES; ANIMALS; EPITOPES, B-LYMPHOCYTE; GENE PRODUCTS, TAT; HIV ANTIBODIES; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; IMMUNIZATION; MACACA; MICE; MICE, INBRED BALB C; RABBITS; TRANS-ACTIVATION (GENETICS); VIRUS REPLICATION;

EID: 5444220596     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.80365-0     Document Type: Article

References (53)

1. Alape-Giron, A., Miranda-Arrieta, K., Cortes-Bratti, X., Stiles, B. G. & Gutierrez, J. M. (1997). A comparison of in vitro methods for assessing the potency of therapeutic antisera against the venom of the coral snake Micrurus nigrocinctus. Toxicon 35, 573-581.
2. Albini, A., Benelli, R., Giunciuglio, D., Cai, T., Mariani, G., Ferrini, S. & Noonan, D. M. (1998). Identification of a novel domain of HIV tat involved in monocyte chemotaxis. J Biol Chem 273, 15895-15900.
3. Bartz, S. R. & Emerman, M. (1999). Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. J Virol 73, 1956-1963.
4. Belliard, G., Romieu, A., Zagury, J. F. & 8 other authors (2003). Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals. Vaccine 21, 3186-3199.
5. Bennasser, Y., Badou, A., Tkaczuk, J. & Bahraoui, E. (2002). Signaling pathways triggered by HIV-1 Tat in human monocytes to induce TNF-α. Virology 303, 174-180.
6. + T lymphoblastoid Jurkat cells. Eur J Immunol 27, 2805-2811.
7. Boykins, R. A., Ardans, J. A., Wahl, L. M., Lal, R. B., Yamada, K. M. & Dhawan, S. (2000). Immunization with a novel HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice. Peptides 21, 1839-1847.
8. Brake, D. A., Debouck, C. & Biesecker, G. (1990a). Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat. J Cell Biol 111, 1275-1281.
9. Brake, D. A., Goudsmit, J., Krone, W. J., Schammel, P., Appleby, N., Meloen, R. H. & Debouck, C. (1990b). Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1. J Virol 64, 962-965.
10. Cafaro, A., Caputo, A., Fracasso, C. & 16 other authors (1999). Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 5, 643-650.
11. Cartier, C., Sivard, P., Tranchat, C., Decimo, D., Desgranges, C. & Boyer, V. (1999). Identification of three major phosphorylation sites within HIV-1 capsid. Role of phosphorylation during the early steps of infection. J Biol Chem 274, 19434-19440.
12. Chirmule, N., Than, S., Khan, S. A. & Pahwa, S. (1995). Human immunodeficiency virus Tat induces functional unresponsiveness in T cells. J Virol 69, 492-498.
13. 15N-labeled amino acids for NMR structural studies. J Pept Res 54, 427-435.
14. Dayton, A. I., Sodroski, J. G., Rosen, C. A., Goh, W. C. & Haseltine, W. A. (1986). The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 44, 941-947.
15. Ensoli, B., Barillari, G., Salahuddin, S. Z., Gallo, R. C. & Wong-Staal, F. (1990). Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345, 84-86.
16. Ensoli, B., Buonaguro, L., Barillari, G., Fiorelli, V., Gendelman, R., Morgan, R. A., Wingfield, P. & Gallo, R. C. (1993 . Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67, 277-287.
17. Felber, B. K. & Pavlakis, G. N. (1988). A quantitative bioassay for HIV-1 based on trans-activation. Science 239, 184-187.
18. Frankel, A. D. & Pabo, C. O. (1988). Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55, 1189-1193.
19. Gallo, R. C. (1999). Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci U S A 96, 8324-8326.
20. Ganju, R. K., Munshi, N., Nair, B. C., Liu, Z. Y., Gill, P. & Groopman, J. E. (1998). Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol 72, 6131-6137.
21. Gibellini, D., Bassini, A., Pierpaoli, S., Bertolaso, L., Milani, D., Capitani, S., La Placa, M. & Zauli, G. (1998). Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 160, 3891-3898.
22. Goldstein, G. (1996). HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 2, 960-964.
23. Goldstein, G., Manson, K., Tribbick, G. & Smith, R. (2000). Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine 18, 2789-2795.
24. Goldstein, G., Tribbick, G. & Manson, K. (2001). Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains. Vaccine 19, 1738-1746.
25. Gringeri, A., Santagostino, E., Muca-Perja, M. & 8 other authors (1999). Tat toxoid as a component of a preventive vaccine in seronegative subjects. J Acquir Immune Defic Syndr Hum Retrovirol 20, 371-375.
26. Hauber, J., Perkins, A., Heimer, E. P. & Cullen, B. R. (1987). Transactivation of human immunodeficiency virus gene expression is mediated by nuclear events. Proc Natl Acad Sci U S A 84, 6364-6368.
27. Herrmann, C. H. & Rice, A. P. (1995). Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J Virol 69, 1612-1620.
28. Huang, L., Bosch, I., Hofmann, W., Sodroski, J. & Pardee, A. B. (1998). Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol 72, 8952-8960.
29. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 680-685.
30. Le Buanec, H. & Bizzini, B. (2000). Procedures for preparing biologically inactive, but immunogenic HIV-1 Tat protein (Tat toxoid) for human use. Biomed Pharmacother 54, 41-54.
31. Moreau, E., Hoebeke, J., Zagury, D., Muller, S. & Desgranges, C. (2004). Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen. J Virol 78, 3792-3796.
32. Neimark, J. & Briand, J. P. (1993). Development of a fully automated multichannel peptide synthesizer with integrated TFA cleavage capability. Pept Res 6, 219-228.
33. Noonan, D. M., Gringeri, A., Meazza, R. & 7 other authors (2003). Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers. J Acquir Immune Defic Syndr 33, 47-55.
34. Olszewska, W., Obeid, O. E. & Steward, M. W. (2000). Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity. Virology 272, 98-105.
35. Pauza, C. D., Trivedi, P., Wallace, M. & 7 other authors (2000). Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci U S A 97, 3515-3519.
36. Re, M. C., Furlini, G., Vignoli, M. & 7 other authors (1995). Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 10, 408-416.
37. Re, M. C., Vignoli, M., Furlini, G., Gibellini, D., Colangeli, V., Vitone, F. & La Placa, M. (2001). Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 21, 81-89.
38. Reiss, P., de Wolf, F., Kuiken, C. L., de Ronde, A., Dekker, J., Boucher, C. A., Debouck, C., Lange, J. M. & Goudsmit, J. (1991). Contribution of antibody response to recombinant HIV-1 gene-encoded products net, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals. J Acquir Immune Defic Syndr 4, 165-172.
39. Rhim, H., Echetebu, C. O., Herrmann, C. H. & Rice, A. P. (1994). Wild-type and mutant HIV-1 and HIV-2 Tat proteins expressed in Escherichia coli as fusions with glutathione S-transferase. J Acquir Immune Defic Syndr 7, 1116-1121.
40. Richardson, M. W., Mirchandani, J., Duong, J., Grimaldo, S., Kocieda, V., Hendel, H., Khalili, K., Zagury, J. F. & Rappaport, J. (2003). Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 57, 4-14.
41. Rodman, T. C., To, S. E., Hashish, H. & Manchester, K. (1993). Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci U S A 90, 7719-7723.
42. Rodman, T. C., Lutton, J. D., Jiang, S., Al-Kouatly, H. B. & Winston, R. (2001). Circulating natural IgM antibodies and their corresponding human cord blood cell-derived Mabs specifically combat the Tat protein of HIV. Exp Hematol 29, 1004-1009.
43. Rubartelli, A., Poggi, A., Sitia, R. & Zocchi, M. R. (1998). HIV-1 Tat: a polypeptide for all seasons. Immunol Today 19, 543-545.
44. + T cells. J Immunol 162, 2427-2431.
45. Silvera, P., Richardson, M. W., Greenhouse, J. & 7 other authors (2002). Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol 76, 3800-3809.
46. Simonsen, O., Schou, C. & Heron, I. (1987). Modification of the ELISA for the estimation of tetanus antitoxin in human sera. J Biol Stand 15, 143-157.
47. Steinaa, L., Sorensen, A. M., Nielsen, J. O. & Hansen, J. E. (1994). Antibody to HIV-1 Tat protein inhibits the replication of virus in culture. Arch Virol 139, 263-271.
48. Tahtinen, M., Ranki, A., Valle, S. L., Ovod, V. & Krohn, K. (1997). B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains. Biomed Pharmacother 51, 480-487.
49. Tikhonov, I., Ruckwardt, T. J., Hatfield, G. S. & Pauza, C. D. (2003). Tat-neutralizing antibodies in vaccinated macaques. J Virol 77, 3157-3166.
50. Tosi, G., Meazza, R., de Lerma Barbaro, A. & 7 other authors (2000). Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR. Eur J Immunol 30 1120-1126.
51. Viscidi, R. P., Mayur, K., Lederman, H. M. & Frankel, A. D. (1989). Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 246, 1606-1608.
52. Westendorp, M. O., Frank, R., Ochsenbauer, C., Stricker, K., Dhein, J., Walczak, H., Debatin, K. M. & Krammer, P. H., (1995 . Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375, 497-500.
53. Zagury, J. F., Sill, A., Blattner, W. & 12 other authors (1998). Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1, 282-292.